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Abstract
Invasive Candidiasis (IC) presents a global mortality rate greater than 40%, 
occupying the fourth place worldwide as the most frequent opportunistic nosoco-
mial disease. Although the genus Candida consists of around 200 species, only 20 
are reported as etiological agents of IC, being Candida albicans the most frequent 
causal agent. Even when there is a broad range of antifungals drugs for Candida 
infections, azoles, polyenes, and echinocandins are considered among the most 
effective treatment. However, there is some incidence for antifungal resistance 
among some Candida strains, limiting treatment options. Several molecular mech-
anisms with antifungal agents have been reported for C. albicans where insertions, 
deletions, and point mutations in genes codifying target proteins are frequently 
related to the antifungal drug resistance. Furthermore, gene overexpression is also 
frequently associated to antifungal resistance as well as an increase in the activ-
ity of proteins that reduce oxidative damage. This chapter summarizes the main 
molecular mechanisms to C. albicans antifungal drug resistance, besides offering 
an overview of new antifungal agents and new antifungal targets to combat fungal 
infections.
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1. Introduction
Candida albicans is the most important opportunistic commensal yeast that 
asymptomatically colonizes the skin, oral cavity, gastrointestinal and genitourinary 
tracts in healthy people. However, it can cause superficial and invasive infections, 
especially in immunocompromised individuals [1–3]. Actually, invasive infections 
due to Candida species are considered among the main causes of morbidity and 
mortality in hospitalized patients. Although there are at least 15 Candida spe-
cies related to human disease, more than 90% of the invasive diseases are related 
to C. albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis, and 
Candida krusei [4–6]. C. albicans infections is considered the fourth most common 
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opportunistic infection in hospitals. Invasive candidiasis (IC) is fatal in about 42% 
of the reported cases, despite the use of antifungal therapies [7, 8].
Nowadays, the most widely used antifungal drugs for IC include: A) azoles, 
for instance fluconazole (FLZ), itraconazole (ITC), voriconazole, posaconazole, 
isavuconazole; B) polyenes such as amphotericin B (AMB); C) echinocandins like 
caspofungin, micafungin, and anidulafungin [9–11].
These antifungal compounds act on different parts of the fungal cell (Figure 1).  
Azoles interrupt the ergosterol biosynthesis, the main component of the fungal 
membranes [10, 12, 13]. Polyenes such as AMB interact with ergosterol making pores 
in the cell membrane [10, 12–14]; while echinocandins act blocking the synthesis of  
β-d-glucan located in the fungal cell wall [13, 15]. The gradual risk increment for 
Candida infection and the greater use of antifungal agents has increased resistance 
towards Candida spp. Pharmacological failures in Candida spp. treatments have 
drawn attention to the problem of resistance to antifungals and their molecular mech-
anisms. C. albicans inherently is susceptible to azoles, polyenes, and echinocandins. 
Mono-resistance to azoles or echinocandins has been reported, as well as combined 
resistance to azoles and amphotericin, but resistance to multiple compounds that 
covers all three drug classes is a rare phenomenon and few cases have been reported in 
C. albicans [10, 12, 16].
The following chapter offers an overview of the main genetic mechanisms 
contributing to the antifungal resistance in C. albicans, besides giving an approach 
for alternative-compounds proposed against their infection.
2. Molecular mechanisms of antifungal resistance
2.1 Azoles
Fungi cell membrane is mainly integrated by ergosterol, a sterol contributing to 
several cellular functions, besides modulating membrane fluidity and the structure 
and function of membrane proteins. The azoles mechanism of action is to inhibit 
Figure 1. 
Mechanisms of action of main antifungals families in the fungal cell. (a) Azoles disrupt the ergosterol synthesis 
by inhibiting the enzyme 14-α-lanosterol demethylase (ERG11) involved in the transformation of lanosterol 
into ergosterol in the endoplasmic reticulum. (b) Polyenes disrupt the cell membrane by binding to ergosterol 
resulting in pore formation. (c) Echinocandins inhibit 1,3-β-d-glucan synthase (FKS ½) which causes 
disruption of the cell wall.
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14α-lanosterol demethylase, encoded by the ERG11 gene, which converts lanosterol 
to ergosterol in the cell membrane (Figure 1). This enzyme contains an iron pro-
toporphyrin unit in its active site. Azoles bind to iron causing the blockage of the 
ergosterol biosynthetic pathway [17–19]. The interruption of ergosterol synthesis 
allows the accumulation of 14α-methyl sterols, which alters the membrane’s stabil-
ity, permeability, and the action of the enzymes bound to it [20].
The evolution of antimicrobial agent’s resistance is common, as there are many 
microbes able to develop strategies against drugs action. The incremented azoles 
resistance is mainly a result of their fungistatic rather than fungicidal nature [17–19]. 
The mechanisms of resistance to azole antifungal agents have been elucidated in 
Candida spp. species and can be classified mainly as: 1) changes in cell wall or in 
plasma membrane, leading to poor drug absorption; 2) alterations in the affinity 
of the target drug (i.e. ERG11 gene), due to a site mutation or its overexpression; 3) 
drug efflux mediated by membrane transporter proteins belonging to the transport-
ers of the ATP-binding cassette (ABC), namely CDR1 and CDR2 or the transporter 
of the major facilitator superfamily (MFS), CaMDR1; 4) biofilm formation [18–21]. 
Although the resistance described in C. albicans strains is usually a combination of 
the mechanisms mentioned above (Figure 2) [16].
2.1.1 Mutations of the ERG11 target enzyme
Mutations in the C. albicans ERG11 gene reduce the affinity for fluconazole and 
have a moderate effect on posaconazole [17–19]. Several point mutations have been 
identified in the ERG11 gene. In resistant strains, there are more than 140 substitu-
tions reported, most of them have a functional additive effect. Two of the most 
common alterations in C. albicans (R467K and G464S), are located near the heme-
binding site [20]. Other substitutions related to resistance are A114S, Y132H, Y132F, 
K143R, Y257H, and K143Q, which contribute to a significant increased resistance 
(more than four times) to fluconazole and voriconazole [22].
Some clinical isolates share common mutations with environmental azole-
resistant strains, suggesting that some azole-resistant clinical isolates could have 
their origin in the environment [23]. This resistance appears to be driven by the 
Figure 2. 
Schematic overview of the main mechanisms of drug resistance against azoles, AMB, and echinocandins adopted 
by Candida albicans. (a) Alteration of the enzyme target (azoles and echinocandins), (b) overexpression of 
drug efflux proteins (azoles), (c) Reduction of sterols in the plasma membrane (AMB), (d) increased stress 
tolerance and altered the fungal cell wall (echinocandins and AMB).
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agricultural use of azoles. In patients without azoles treatment, resistance has been 
identified derived from the environment. These cases involved a Cyp51A substitu-
tion at position 98 (from leucine to histidine), and a 34 base tandem repeat (TR) 
in the cyp51A promoter, leading to overexpression. Both changes are necessary to 
confer resistance. In particular, these resistant isolates can be crossed with suscep-
tible strains, suggesting that resistance could be transferred through the sexual 
cycle. Strains with these alterations have emerged throughout Europe and beyond. 
Additionally, a new environmentally selected resistance mutation (TR46, Y121F, 
T289A) was reported among patients in the Netherlands [20].
2.1.2 Dysregulation of the target enzyme ERG11
One way to decrease the drug effective concentration is the overexpression 
of ERG11 [17]. This overexpression is common among azole-resistant C. albicans 
clinical isolates. This contributes directly to resistance, since an increase in the 
target requires more drug for inhibition, reducing susceptibility [19]. ERG11 
overexpression arises either from genetic dosing through gene duplication or from 
positive regulation of the gene by trans-acting factors [23]. Multiple mechanisms 
explain the constitutive overexpression of ERG11 in azole-resistant clinical strains. 
First, amplification of the ERG11 gene can occur by the formation of an isochromo-
some with two copies of the left arm of chromosome 5 [i (5 L)], in which ERG11 
resides, or by duplication of the entire chromosome. Second, the activation of 
mutations in the gene encoding the transcription factor Upc2 positively regulates 
most of the ergosterol biosynthesis genes [18, 20].
2.1.3  Alteration of the ergosterol biosynthesis pathway (point mutations in ERG 
genes)
Brief exposures of two to three hours to azoles cause transient upregulation 
of the ERG gene family in C. albicans. These data suggest a common regulation 
of ergosterol biosynthetic pathway in the presence of inhibitors. Longer in vitro 
exposures to azoles (minimum 24 h) leads to constitutive up-regulation of the ERG 
genes decreasing drug susceptibility [23].
Modification of the metabolic pathway can be effective at different points, as 
example, alteration of the last steps of biosynthesis through the inactivation of the 
ERG3 gene results in no toxic methylated sterols production, leading to azole cross-
resistance. Furthermore, mutations in non-essential genes of this pathway (ERG3, 
ERG6, ERG24, and ERG2) also lead to a decrease, or even a total absence, of ergos-
terol in the plasma membrane [17]. Lanosterol demethylase inactivity or defective-
ness due to azoles induce ergosterol depletion and toxic 14α-methyl-3,6-diol sterols 
accumulation. The presence of 14α-methyl sterols can modify the function and 
fluidity of the plasma membrane [21]. The additive mutation in the ERG3 gene 
prevents the formation of this toxic product from 14α-methylfecosterol and leads to 
the accumulation of non-toxic sterols (Mishra, 2007; Shukla, 2016). Although this 
mechanism is not the most frequent one, it has been identified in several clinical 
isolates of C. albicans [23]. Mutations in ERG3 are sufficient to induce azole resis-
tance in Candida spp., but they are rarely associated with high resistance [20].
Four clinically isolated C. albicans erg3 mutants (CA12, CA488, CA490, and 
CA108) were reported as resistant to fluconazole, voriconazole, itraconazole, keto-
conazole, and clotrimazole under CLSI test conditions. Importantly, CA12 and CA108 
retained an azole-resistant phenotype even when tested in the presence of FK506, a 
multi-drug flux inhibitor. In contrast, CA488, CA490, along with three isolates (CA6, 
CA14, and CA177, in which ergosterol comprised more than 80% of the total sterol 
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fraction and ergosta 7,22-dienol was undetectable) exhibited azole sensitive pheno-
types in the inhibitor FK50 presence. CA108 mutant strain contains multiple amino 
acid substitutions in ERG3, but only a single conserved polymorphism (E266D) in 
sterol 14α-demethylase (ERG11). CA12 contains a substitution (W332R) in ERG3 and 
no residue changes in ERG11. Furthermore, CA488 and CA490 were found to harbour 
multiple residue changes in both ERG3 and ERG11 [24]. Furthermore, the residue 193 
in ERG3 was found to play an important role in azole resistance [25].
2.1.4 Efflux pumps
A mechanism to decrease the azoles intracellular concentration is increasing their 
output. This class of resistance is mediated by the activity of transport systems such 
as the pleiotropic drug resistance (PDR) class of ATP-binding cassette transporters 
(ABC) and major facilitators superfamily (MFS) transporters [17]. These membrane 
proteins translocate compounds across cell membranes actively using different 
energy sources. ABC proteins are primary transporters that use ATP hydrolysis. MFS 
pumps are secondary transporters that use the motive force of the proton across the 
plasma membrane. Both types of transporters contain distinctive protein domains 
that confer substrate specificity: nucleotide-binding domains (NBD) in ABC pumps 
and transmembrane domains (TMD) in ABC and MFS pumps. Fungal PDR proteins 
appear to share common features on both sides of the two TMDs that separate the 
cytosolic from the outer cytosolic space [18, 26]. This probably reflects the fact that 
the cytosolic part is the motor that drives the transport of a variety of substrates 
through the lipid bilayer through the core of the protein into the outer cytosolic 
space or the outer layer of the lipid bilayer [26].
C. albicans contains 28 ABC proteins and 96 potential MFS transporters [18]. 
In this species, the main transporters, related to resistance, of the ABC proteins 
are CDR1 and CDR2 (resistance drugs to Candida 1 and 2) [21], while for MFS it is 
MDR1 (Multidrug Resistance 1). CDR1 and CDR2 overexpression improves drug 
output and reduces its accumulation in cells [23]. Positive regulation of MDR1 
results in increased azole output [17]. Several cis-acting regulatory elements 
responsible for the regulation of the CDR1 and CDR2 genes have been identified. 
Promoter deletion studies have revealed five different regulatory elements in the 
CDR1 promoter, including one BEE (basal expression element), one DRE (drug-
sensitive element), two SRE (steroid sensitive element), and one NRE (negative 
regulatory element). Internal deletions of the BEE and DRE motifs in the CDR1 
promoter affect baseline CDR1 expression and drug-induced expression, respec-
tively. SRE1 and SRE2 are involved in steroid hormone responses: SRE1 responds 
only to progesterone and SRE2 to progesterone and β-estradiol. Finally, the dele-
tion of the NRE motif leads to an increase in the baseline expression of CDR1. In 
contrast to CDR1, the CDR2 promoter contains only one DRE motif. Among these 
diverse cis-acting elements, DRE is the only element involved in constitutive high 
expression and transient up-regulation of CDR1 and CDR2. In C. albicans, CDR1 is 
the main contributor to azole resistance among ABC transporters [23, 26].
In C. albicans a gene encoding a CaNdt80p protein similar to the Saccharomyces 
cerevisiae meiosis-specific transcription factor Ndt80p has been identified. Alteration 
of CaNdt80 affects the basal expression of CDR1 and reduces its ability for up-
regulation in the presence of miconazole. More recently, Ndt80p was involved in the 
global effect of azole resistance through its regulon, including several genes impli-
cated in ergosterol metabolism [23]. Additionally, MDR1 is the only MFS transporter 
involved in the azole resistance of clinical isolates. MDR1 usually does not express 
detectable levels in fluconazole-susceptible isolates but is constitutively up-regulated 
in some fluconazole-resistant strains. A region called BRE (benomyl response 
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element) or MDRE (MDR1 drug resistance element), respectively, was identified. 
This region is responsible for the constitutively high expression of MDR1 in flucon-
azole-resistant isolates. Hyperactive alleles confer a constitutive overexpression of 
MDR1 and therefore, resistance to fluconazole [23]. MDR1 expression in C. albicans 
cells is enhanced by benomyl, methotrexate, and several other unrelated drugs, and 
found to be more pronounced in some of the azole-resistant clinical isolates [21].
The up-regulation of ABC and MFS transporters is mediated by specific regula-
tions in resistant fungal pathogens. Point mutations defined as gain-of-function 
(GOF) mutations in these regulators confer an inherently high level of expression of 
the transporters in drug-resistant strains. GOF mutations in the transcription factor 
Upc2p led to increased resistance to fluconazole in C. albicans [17]. GOF mutations 
in the transcription factors TAC1 and MRR1 lead to upregulation of the CDR1/CDR2 
and MDR1 drug efflux pumps, respectively [16, 18]. An important question related 
to strategies to overcome efflux-mediated antifungal resistance is the relative contri-
bution of each efflux pump protein to clinically significant antifungal resistance in  
C. albicans. It is now clear that the CDR1, CDR2, and MDR1 transporters are the 
main efflux pumps that mediate resistance of C. albicans to azole drugs. However, 
MDR1 is relatively specific for fluconazole, while many azole drugs can act as sub-
strates for CDR1 and CDR2. Interestingly, several fluconazole-resistant C. albicans 
isolates overexpress only CDR1 and CDR2, but not MDR1, while other strains over-
express only MDR1, reflecting the existence of at least two different transcriptional 
pathways that are responsible for the upregulation of these genes in azoles [26].
2.2 Polyenes
The potent fungicidal activity of polyenes derives from their ability to selec-
tively bind sterol at the fungal cell membrane (Figure 1). Four models have been 
proposed as the mode of action for polyenes: 1) the pore formation model, 2) the 
surface adsorption model, 3) the sterol sponge model, and 4) the oxidative damage 
model [14]. The pore formation model is the most studied mechanism, where poly-
enes are directly intercalated with the ergosterol membrane forming ion channels 
that permeabilize and kill yeast cells [14, 27]. Additionally, indirect mechanisms of 
fungal cells damage have been identified due to the effect of polyene compounds, 
such as those mediated by reactive oxygen species (ROS) and by the secretion of 
interleukin-1β (IL-1β) by host cells [28, 29].
The polyene AMB is a broad-spectrum drug and is one of the main antifungals 
used for ICs [10, 14]. AMB is heptane isolated from Streptomyces nodosus producing 
high toxicity. Hence, a liposomal AMB (Ambisome R) has been developed to mini-
mize side effects and increase treatment efficacy [10, 14, 30, 31]; however, the high 
costs of this drug limited its use. Resistance to AMB is rare, despite 50 years of clinical 
use as monotherapy, although resistant C. albicans strains have been found in different 
studies [32–35]. The alterations in the composition of the sterols and phospholipids of 
the membrane, the regulation of oxidative stress, and alterations of the fungal cell are 
the more frequent resistance mechanisms described for AMB in fungi [10, 12, 14]. In 
C. albicans, resistance to AMB is associated with ergosterol replacement by a precur-
sor molecule or by sterols reduction at the plasma membrane (Figure 2) [10, 12, 14].
2.2.1  Alteration in the composition of sterols in the cell membrane (mutations in 
ERG genes)
The most common mechanism for acquired resistance to AMB in C. albicans is 
attributed to alterations in the composition of sterols of the fungal cell membrane 
[10, 12, 14, 36]. Different mutations in ERG genes (ERG11, ERG3, ERG2, and 
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ERG6) have been associated with this mechanism in Candida spp. [14, 37, 38]. Loss 
of function of the ERG11 and ERG3 genes (lanosterol 14α-demethylase and C-5 
sterol desaturase, respectively), leads to the exchange of ergosterol for alternative 
sterols such as lanosterol, eburicol, and 4,14-dimethyl-zymosterol in the mem-
brane of C. albicans, [14, 36, 39]. Resistance to AMB in C. albicans is also associated 
with an aminoacidic substitution in ERG11 and with ERG5 (sterol desaturase C-22) 
disfunction, again associated with an alternative membrane sterol composition 
[14, 39, 40]. In other Candida spp., the inactivation of ERG6 [11, 14, 37] and ERG2 
had a similar effect [11, 14]. Resistance to AMB is rarely found in combination 
with resistance to other antifungal drugs, although certain mutations that induce 
resistance to polyenes can lead to cross-resistance to azoles [14, 36, 41].
2.2.2 Response to oxidative stress and alterations in the cell wall
Fungal resistance mechanisms are also related to oxidative stress regulation, 
allowing the cell to tolerate exposure to AMB [14, 30]. In C. albicans, one of the 
described mechanisms of stress tolerance to AMB includes the heat shock protein 
90 (Hsp90) molecular chaperone, which regulates a large number of proteins 
involved in several fungal cellular processes [42, 43]. In addition to alterations in 
the composition of sterols in the plasma membrane and the regulation of oxida-
tive stress, studies in fungi have correlated resistance to AMB with fungal cell wall 
alterations [14, 44, 45]. In AMB resistant C. tropicalis strains, an enlargement of 
the cell wall has been observed with increased levels of 1,3-β-glucans [14, 44], 
suggesting an affectation in the penetration of AMB through the cell wall [14, 45].
2.3 Echinocandins
Echinocandins are lipo-peptides that inhibit 1,3-β-d-glucan synthetase, which 
is responsible for the biosynthesis of 1,3-β-d-glucan, one of the main components 
of the fungal cell wall, causing osmotic instability and therefore the death of fungal 
cells (Figure 1) [10, 13]. This class of drugs has certain advantages attributable to 
its effects on the fungal cell wall, including a lower risk of side effects since animal 
cells do not have this structure [10]. Echinocandins have a limited spectrum, but for 
Candida species, they have broad fungicidal activity. The 1,3-β-d-glucan synthetase 
target comprises a GTP binding protein Rho, which helps regulate the biosynthetic 
capacity of glucan synthetase, and a catalytic subunit, FKS, which encodes three 
related genes, FKS1, FKS2, and FKS3. FKS1 is essential in C. albicans and other 
Candida spp. Whereas FKS1 and FKS2 are functionally redundant in C. glabrata, 
FKS3 is very low expressed compared to other genes [46], not being a significant 
contributor to biosynthetic capacity in general.
Echinocandins are the first major new class of antifungal drugs on the market in 
decades. Consequently, it is of vital importance to assess the nature of the resistance 
mechanism to this class of drugs. Mutations that affect the target site are the most 
likely resistance mechanism that exists (Figure 2), since unlike azoles, echinocan-
dins are poor substrates for drug exit through efflux transporters, ruling out this 
mechanism of resistance [10, 13]. Specific mutations have already been reported in 
two highly conserved regions of the Fks1 subunit of glucan synthetase, a membrane 
protein, which can confer resistance in vitro in Candida isolates to caspofungin, the 
first echinocandin approved for the treatment of yeast infections [10, 13, 47, 48]. 
Other ways in which there may be the acquisition of resistance to echinocandins in 
C. albicans is through different response pathways to cellular stress, as well as some 




2.3.1 Acquired FKS mutations
Resistance-associated amino acid substitutions occur in two highly con-
served hot-spot (HS) regions of the FKS genes. The residues they encompass are 
Phe641– Pro649 and Arg1361 in C. albicans and other Candida spp. Substitutions 
of amino acids Ser645 and Phe641 cause 75% resistance in C. albicans [10, 13]. 
Pharmacodynamic studies conducted in murine models infected with C. albicans 
demonstrated that mutations in the FKS1 gene confer resistance to echinocandins 
[48, 49]. Mutations in FKS1 lead to a decrease in the virulence of C. albicans in 
murine models of IC. Furthermore, high doses of caspofungin are effective against 
C. albicans, including resistant isolates that presented point mutations in FKS1 
[50, 51]. Several studies have reported that mutations in the FKS1 gene produce 
changes in the morphology of the cell wall of C. albicans, observing a decrease in 
1,3-β-d-glucan levels in contrast to the increased amount of chitin in response to 
echinocandin exposure [51]. Data suggest that increased chitin in the C. albicans 
cell wall could provide a window of opportunity to acquire mutations in FKS1, 
even without exposure to caspofungin [52].
2.3.2 Adaptive stress responses
The fungal cell wall is a dynamic structure that changes during growth and 
development, requires 1,3-β-d-glucan crosslinking, an essential polymer for the 
survival of the fungal cell. Echinocandins alter the integrity of the cell wall and 
induce stress in the cell. In response to this, the fungal cell possesses a repertoire 
of mechanisms to protect the cell against such destabilization. Protection against 
cell wall weakening is induced through a variety of stress adaptation mechanisms, 
which involve protein kinase C (PKC), calcineurin, and Hsp90 [10, 13]. Stress 
signals in the cell wall are transmitted through the Rho GTPase, which mobilizes 
various effectors. Its activation alters several carbohydrate polymers along with the 
structure and remodelling of the cell wall. The Hsp90 heat shock protein organizes 
a cellular stress response circuit that has a major impact on resistance to echino-
candins. Also, the genetic or chemical modulation of the Hsp90 protein reduces 
tolerance to echinocandins [52]. In response to the inhibition of FKS by the action 
of echinocandins, a greater amount of chitin is produced helping to maintain the 
integrity of the cell wall as chitin replaces 1,3-β-d-glucan, thus reducing sensitivity 
to drugs [10, 13, 48].
3. New antifungals
The resistance of C. albicans and other pathogenic fungi to current antifungal 
agents has established the need to find new antifungal targets with a novel mecha-
nism of action. Resistant strains are increasing in number for some classes of 
antifungal agents, particularly for azoles and echinocandins [53]. Consequently, 
it is necessary to face the challenge of successfully managing fungal infections. To 
achieve this, one of the main points is the continuation of the development of new 
antifungal drugs [54]. The main issues faced by the development of new drugs 
are: 1) they must have a broad spectrum against emerging filamentous yeasts 
and fungi and 2) they must have a more efficient fungicidal activity to eliminate 
pathogens quickly and totally [55–59]. Besides, invasive candidiasis occurs in very 
frail patients who do not tolerate much organ toxicity, since such patients are often 
taking many other therapeutic agents, so drug–drug interactions must be care-
fully considered [60].
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3.1 Discovery and development of new antifungal drugs
This part of the chapter provides an overview of ongoing efforts to develop 
new classes of antifungal drugs (Table 1). Although there are several strategies for 
the development of these drugs, these include those obtained from new chemical 
agents, from reusing existing drugs, from peptides with antimicrobial properties, 
and finally from natural compounds extracted from plants [10, 55, 58].
Several new chemical-antifungals are designed specifically to target either 
1,3-β-d-glucan (such as Rezafungin and Ibrexafungerp) or ergosterol (such as the 
compound VT-1161). These compounds are very specific for fungal infections or 
they have a longer half-life, offering better efficacy [58, 60–62]. At the same time, 
several of these antifungal agents have new targets and subsequently, new mecha-
nisms of action. For instance, fosmanogepix, formerly APX001, and aureobasidin 
A, which act by inhibiting inositol acyltransferase, and inositol phosphorylceramide 
synthase, respectively [63, 64]. Efungumab (or Mycograb) and geldanamycin-like 
agents can inhibit the HSP90 chaperone, which has been also shown to confer resis-
tance to antifungals [65, 66]. The AR-12 compound deregulates chaperone’s activity 
by blocking fungal acetyl-CoA synthase [67]. The T-2307 compound is an aryl-
amidine that inhibits the respiratory chain complex and is active against yeast and 
filamentous fungi [68]. Finally, the VL-2397 compound has a similar structure to the 
ferrichrome siderophore, and whose mechanism of action or its target is unknown, 
but it is known to be transported by the Sit1 protein [69]. Some compounds that 
have been already tested for other types of diseases are now receiving a new focus as 
antifungals. These include two compounds that enhance the antifungal activity, such 
as rifampin, which acts on RNA polymerase [70], and verapamil, which acts on a 
calcium channel [71]. We have also given importance to alternative compounds such 
as peptides and plant extracts; many molecules are actually studied with promising 
results, especially against C. albicans. Some peptides such as lysozyme, lactoferrin, 
defensins, Histatin-5, and cathelicidins are known to have antifungal properties. The 
main mechanism of action is due to the enhancement of substances traffic through 
the fungal membrane, which favours permeabilization [10, 72–76]. Plant extracts are 
another prominent source of new antifungals, they can act either alone or synergisti-
cally with existing antifungals to improve their function. The compounds extracted 
from plants are essential oils, terpenes, and flavonoids among many others. They 
have diverse mechanisms of action, such as alteration of the plasma membrane, 
binding to ergosterol, induction of apoptosis, inhibition of growth, filamentation, 
and biofilm formation in C. albicans [10, 77–81].
3.2 New targets and alternative approaches
Despite the efforts made to discover, repositioning, or create new antifungal 
drugs, it is imperative to find new targets to help eliminating Candida spp. infec-
tion. The new antifungal targets include biosynthetic and signal transduction 
pathways, which are key players for fungal survival processes. The sphingo-
lipids biosynthesis is a biosynthetic pathway considered as a promising target. 
Sphingolipids are a part of cell membranes, that act as signalling molecules 
regulating processes such as apoptosis. As fungal sphingolipids are structurally 
different to mammalian sphingolipids, they are excellent candidates for antifungal 
design [82]. The heat-shock proteins (Hsps) represent another potential antifungal 
target as they control several basic physiological activities, and heat-shock protein 
disruption in C. albicans inhibits growth or reverses tolerance to antifungals [83]. 
A recently studied pathway as a potential target is the ionic homeostasis signalling 
pathway, which is central to the fungus survival by regulating gene expression, 
Candida albicans
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morphological transition, response to stress, and resistance to antifungals [84]. The 
Ras-cAMP-PKA signal transduction pathway is essential for cellular metabolism 
and controls morphogenesis, adhesion, and biofilm formation, making the inacti-
vation of this signalling cascade attractive as a target for new antifungals [85].
Finally, an alternative approach to conventional antifungal drugs is the use of 
nanotechnology, which produces the so-called “nanoantibiotics”. These nanoantibi-
otics are unique due to their improved physicochemical properties, such as reduced 
toxicity and biocompatibility as well as their size that must be less than 100 nm 
[86]. The antimicrobial properties of silver have been known for a long time, so sil-
ver nanoparticles were tested as antimicrobials and showed potent activity against 
drug-resistant fungal biofilms [87].
4. Conclusions
A better understanding of the resistance mechanisms of azoles, polyenes, and 
echinocandins, along with the discovery of new cellular and clinical factors promot-
ing resistance, will facilitate the design of more effective strategies to overcome and 
prevent resistance to antifungal agents. Even though several biomedical research 
offer a window hoping to reduce the incidence of C. albicans and the complications 
those systemic infections by this fungus entail; the quest for new targets with novel 
mechanisms of action continues to be the priority.
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